491 related articles for article (PubMed ID: 28493410)
1. Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma.
Chang H; Jung W; Kim A; Kim HK; Kim WB; Kim JH; Kim BH
APMIS; 2017 Aug; 125(8):690-698. PubMed ID: 28493410
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
[TBL] [Abstract][Full Text] [Related]
3. Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group.
Chang H; Jung WY; Kang Y; Lee H; Kim A; Kim HK; Shin BK; Kim BH
Oncotarget; 2016 Dec; 7(49):80426-80434. PubMed ID: 27741514
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
[TBL] [Abstract][Full Text] [Related]
5. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
[TBL] [Abstract][Full Text] [Related]
6. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
Chovanec M; Cierna Z; Miskovska V; Machalekova K; Svetlovska D; Kalavska K; Rejlekova K; Spanik S; Kajo K; Babal P; Mardiak J; Mego M
Oncotarget; 2017 Mar; 8(13):21794-21805. PubMed ID: 28423520
[TBL] [Abstract][Full Text] [Related]
8. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.
Cimino-Mathews A; Thompson E; Taube JM; Ye X; Lu Y; Meeker A; Xu H; Sharma R; Lecksell K; Cornish TC; Cuka N; Argani P; Emens LA
Hum Pathol; 2016 Jan; 47(1):52-63. PubMed ID: 26527522
[TBL] [Abstract][Full Text] [Related]
10. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
Teng F; Meng X; Kong L; Mu D; Zhu H; Liu S; Zhang J; Yu J
Transl Res; 2015 Dec; 166(6):721-732.e1. PubMed ID: 26209749
[TBL] [Abstract][Full Text] [Related]
12. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
13. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
[TBL] [Abstract][Full Text] [Related]
17. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy.
Lim YJ; Koh J; Kim K; Chie EK; Kim B; Lee KB; Jang JY; Kim SW; Oh DY; Bang YJ; Ha SW
Radiother Oncol; 2015 Oct; 117(1):165-70. PubMed ID: 26235847
[TBL] [Abstract][Full Text] [Related]
18. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
[TBL] [Abstract][Full Text] [Related]
19. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.
Shi F; Shi M; Zeng Z; Qi RZ; Liu ZW; Zhang JY; Yang YP; Tien P; Wang FS
Int J Cancer; 2011 Feb; 128(4):887-96. PubMed ID: 20473887
[TBL] [Abstract][Full Text] [Related]
20. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
